Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention | Phase |
|---|---|---|
|
HIV |
Drug: 1% tenofovir gel |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Open-Label Randomized Controlled Trial to Assess the Implementation Effectiveness and Safety of 1% Tenofovir Gel Provision Through Family Planning Services in KwaZulu-Natal, South Africa |
- Mean number of returned used applicators [ Time Frame: monthly ] [ Designated as safety issue: Yes ]
Gel use is essential for the effectiveness of tenofovir gel in preventing HIV infection. The level of gel use was a strong predictor of effectiveness in the exploratory adherence analysis of the CAPRISA 004 trial. Gel use on its own and in relation to coitus were both predictors of the level of protection. Based on the CAPRISA 004 trial which demonstrated a correlation between the number of returned used applicators and the level of effectiveness against HIV infection, the primary endpoint is:
• Mean number of returned used applicators per participant per month
- Clinical and laboratory adverse events [ Time Frame: At each participant contact ] [ Designated as safety issue: Yes ]Any untoward medical occurrence experienced by an enrolled research participant, regardless of association with study product, will be recorded and managed accordingly
- HIV incidence rates [ Time Frame: at study completion ] [ Designated as safety issue: Yes ]
- Pregnancy rates [ Time Frame: Monthly ] [ Designated as safety issue: Yes ]
- Adherence [ Time Frame: Each scheduled study visit ] [ Designated as safety issue: No ]Self-reported adherence to the tenofovir gel dosing strategy as well as factors influencing gel use in relation to sexual activity, condom use, and intravaginal practices
- HIV viral load among HIV seroconverters [ Time Frame: At earliest timepoint after HIV positive result ] [ Designated as safety issue: Yes ]
- Tenofovir resistance among HIV seroconverters [ Time Frame: At study completion ] [ Designated as safety issue: Yes ]
- HSV-2 and HPV incidence rates [ Time Frame: At study completion ] [ Designated as safety issue: Yes ]
- Tenofovir levels [ Time Frame: At study completion ] [ Designated as safety issue: Yes ]Detection of tenovofir from vaginal samples
- Product acceptability [ Time Frame: At stucy completion ] [ Designated as safety issue: No ]Self-reported questionnaire on product acceptability
| Enrollment: | 382 |
| Study Start Date: | October 2012 |
| Study Completion Date: | December 2015 |
| Primary Completion Date: | April 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Intervention
1% tenofovir gel provision through a public sector family planning services with 2-3 monthly provision and monitoring and the use of QI methodology to promote reliable service delivery
|
Drug: 1% tenofovir gel
Participants will be randomized to receive 1% tenofovir gel through either:
|
|
Active Comparator: Control
monthly 1% tenofovir gel provision and monitoring through CAPRISA research clinics
|
Drug: 1% tenofovir gel
Participants will be randomized to receive 1% tenofovir gel through either:
|
Detailed Description:
The CAPRISA 008 trial is a two-arm, open-label, randomized controlled trial that is being conducted at the CAPRISA eThekwini and CAPRISA Vulindlela Clinics and their neighboring public sector family planning services in KwaZulu-Natal, South Africa. Up to 700 consenting sexually active, HIV-uninfected women aged 18 years and older who previously participated in an antiretroviral (ARV) prevention study will be enrolled and followed for a maximum 30 months. All women will be provided with 1% tenofovir gel but will be randomised to either receive their gel through a public sector family planning services with 2-3 monthly provision (intervention arm) or through the CAPRISA research clinics with monthly provision (control arm).
All women in the trial will be provided with the standard package of HIV prevention and reproductive health services. Participants in both study arms will be provided with a supply of single-use, pre-filled applicators of 1% tenofovir gel. While in the study, participants will be advised and supported to follow the CAPRISA 004 pre- and post-dosing strategy, namely BAT24, where the first dose of tenofovir gel is applied within 12 hours before anticipated coitus and a second dose as soon as possible but within 12 hours after coitus, with a maximum of two doses of gel in a 24-hour period.
The primary objective of this trial is to assess the effectiveness of an implementation model for tenofovir gel provision through family planning services.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Age 18 years and older
- Women who previously participated in an ARV prevention study
- Currently utilizing or agreeing to attend designated public sector family planning services
- Able and willing to provide first person informed consent to be screened for, and to enroll in, the study
- Able and willing to provide adequate locator information for study retention purposes
- Sexually active (at least one coital act in the last 3 months prior to screening)
- HIV negative (by HIV testing performed by study staff within 30 days of enrollment)
- Negative pregnancy test performed by study staff within 21 days of enrollment
- Agree to use a non-barrier form of contraceptive
- Agree to adhere to study visits and procedures
Exclusion Criteria:
- Has a creatinine clearance < 50ml/min
- Has any other condition that, based on the opinion of the Investigator or designee, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT01691768
| South Africa | |
| CAPRISA eThekwini Clinical Research Site | |
| Durban, KwaZulu-Natal, South Africa, 4001 | |
| CAPRISA Vulindlela Clinical Research Site | |
| Pietermaritzburg, KwaZulu-Natal, South Africa | |
| Principal Investigator: | Quarraisha Abdool Karim, PhD | Centre for the AIDS Programme of Research in South Africa |
More Information
Additional Information:
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Dr Quarraisha Abdool Karim, Associate Scientific Director, Centre for the AIDS Programme of Research in South Africa |
| ClinicalTrials.gov Identifier: | NCT01691768 History of Changes |
| Obsolete Identifiers: | NCT01645813 |
| Other Study ID Numbers: | CAPRISA008 |
| Study First Received: | July 5, 2012 |
| Last Updated: | January 27, 2016 |
| Health Authority: | South Africa: Medicines Control Council |
Keywords provided by Centre for the AIDS Programme of Research in South Africa:
|
microbicides women HIV prevention PrEP Tenofovir gel |
Additional relevant MeSH terms:
|
Tenofovir Antiviral Agents Anti-Infective Agents Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors |
Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Retroviral Agents Anti-HIV Agents |
ClinicalTrials.gov processed this record on September 27, 2016